Zoetis (ZOE) Stock Forecast & Price Target

30 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ZOE Analyst Ratings

Moderate Buy

4 Buy

7 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Zoetis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ZOE Stock 12 Month Forecast

Average Price Target

€80.94

▲(21.56% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is €80.94 with a high forecast of €102.61 and a low forecast of €71.38. The average price target represents a 21.56% change from the last price of €66.58.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"€61","92":"€92","123":"€123","76.5":"€76.5","107.5":"€107.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":102.6052816,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€102.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.93708548571428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€80.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.3775872,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€71.38</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,76.5,92,107.5,123],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.32,65.41886781538462,68.51773563076924,71.61660344615385,74.71547126153845,77.81433907692308,80.9132068923077,84.0120747076923,87.11094252307691,90.20981033846154,93.30867815384616,96.40754596923077,99.50641378461538,{"y":102.6052816,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.32,63.7520834989011,65.1841669978022,66.61625049670329,68.0483339956044,69.48041749450549,70.91250099340658,72.34458449230769,73.77666799120878,75.20875149010989,76.64083498901098,78.07291848791208,79.50500198681317,{"y":80.93708548571428,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.32,63.016737476923076,63.71347495384615,64.41021243076923,65.10694990769231,65.80368738461539,66.50042486153846,67.19716233846154,67.89389981538461,68.59063729230769,69.28737476923077,69.98411224615384,70.68084972307692,{"y":71.3775872,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":122.333,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.837,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.19,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.646,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.232,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.381,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.084,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.139,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.312,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.46,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.32,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€102.61

Average Price Target€80.94

Lowest Price Target€71.38

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Daniel Clark

Leerink Partners

―

Hold

―

Reiterated

10/01/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Eli Lilly & Co (NYSE: LLY) and Liquidia Technologies (NASDAQ: LQDA)

Jonathan Block

Stifel Nicolaus

―

Hold

―

Reiterated

09/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Dexcom (NASDAQ: DXCM) and Alnylam Pharma (NASDAQ: ALNY)

Steve Scala

TD Cowen

€92.79→€83.87

Buy

25.97%

Upside

Assigned

08/25/26

TD Cowen Sticks to Their Buy Rating for Zoetis (ZTS)

Glen Santangelo

Barclays

€75.84

Hold

13.91%

Upside

Reiterated

08/17/26

Barclays Keeps Their Hold Rating on Zoetis (ZTS)

Daniel Grosslight

Citi

€99.93→€85.65

Buy

28.65%

Upside

Reiterated

08/11/26

Zoetis price target lowered to $96 from $112 at CitiZoetis price target lowered to $96 from $112 at Citi

Erin Wright

Morgan Stanley

€75.84

Buy

13.91%

Upside

Assigned

08/10/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), GoodRx Holdings (NASDAQ: GDRX) and 10x Genomics (NASDAQ: TXG)

David Westenberg

Piper Sandler

€80.3→€71.38

Hold

7.21%

Upside

Reiterated

08/10/26

Zoetis price target lowered to $80 from $90 at Piper SandlerZoetis price target lowered to $80 from $90 at Piper Sandler

Chris Schott

J.P. Morgan

€102.61

Buy

54.11%

Upside

Reiterated

08/10/26

Zoetis (ZTS) Receives a Buy from J.P. Morgan

Brandon Vazquez

William Blair

―

Hold

―

Downgraded

08/08/26

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Protagonist Therapeutics (NASDAQ: PTGX) and Zoetis (NYSE: ZTS)

Andrea Alfonso

UBS

€75.84→€71.38

Hold

7.21%

Upside

Assigned

08/07/26

Zoetis price target lowered to $80 from $85 at UBSZoetis price target lowered to $80 from $85 at UBS

Michael Ryskin

Bank of America Securities

―

Hold

―

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (NASDAQ: BMRN), Zoetis (NYSE: ZTS) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Sidharth Sahoo

HSBC

€124.91→€84.76

Buy

27.31%

Upside

Reiterated

07/06/26

Zoetis price target lowered to $95 from $140 at HSBCZoetis price target lowered to $95 from $140 at HSBC

Jasper Hellweg

Argus Research

―

Hold

―

Downgraded

05/26/26

Zoetis downgraded to Hold from Buy at ArgusZoetis downgraded to Hold from Buy at Argus

Scott Schoenhaus

KeyBanc

―

Hold

―

Reiterated

05/08/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Evolent Health (NYSE: EVH), Zoetis (NYSE: ZTS) and ICU Medical (NASDAQ: ICUI)

Thomas DeBourcy

Nephron

€116.88

Hold

75.55%

Upside

Downgraded

03/05/26

Zoetis downgraded to Hold from Buy at Nephron ResearchZoetis downgraded to Hold from Buy at Nephron Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Daniel Clark

Leerink Partners

―

Hold

―

Reiterated

10/01/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Eli Lilly & Co (NYSE: LLY) and Liquidia Technologies (NASDAQ: LQDA)

Jonathan Block

Stifel Nicolaus

―

Hold

―

Reiterated

09/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (NYSE: ZTS), Dexcom (NASDAQ: DXCM) and Alnylam Pharma (NASDAQ: ALNY)

Steve Scala

TD Cowen

€92.79→€83.87

Buy

25.97%

Upside

Assigned

08/25/26

TD Cowen Sticks to Their Buy Rating for Zoetis (ZTS)

Glen Santangelo

Barclays

€75.84

Hold

13.91%

Upside

Reiterated

08/17/26

Barclays Keeps Their Hold Rating on Zoetis (ZTS)

Daniel Grosslight

Citi

€99.93→€85.65

Buy

28.65%

Upside

Reiterated

08/11/26

Zoetis price target lowered to $96 from $112 at CitiZoetis price target lowered to $96 from $112 at Citi

Erin Wright

Morgan Stanley

€75.84

Buy

13.91%

Upside

Assigned

08/10/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), GoodRx Holdings (NASDAQ: GDRX) and 10x Genomics (NASDAQ: TXG)

David Westenberg

Piper Sandler

€80.3→€71.38

Hold

7.21%

Upside

Reiterated

08/10/26

Zoetis price target lowered to $80 from $90 at Piper SandlerZoetis price target lowered to $80 from $90 at Piper Sandler

Chris Schott

J.P. Morgan

€102.61

Buy

54.11%

Upside

Reiterated

08/10/26

Zoetis (ZTS) Receives a Buy from J.P. Morgan

Brandon Vazquez

William Blair

―

Hold

―

Downgraded

08/08/26

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Protagonist Therapeutics (NASDAQ: PTGX) and Zoetis (NYSE: ZTS)

Andrea Alfonso

UBS

€75.84→€71.38

Hold

7.21%

Upside

Assigned

08/07/26

Zoetis price target lowered to $80 from $85 at UBSZoetis price target lowered to $80 from $85 at UBS

Michael Ryskin

Bank of America Securities

―

Hold

―

Reiterated

07/28/26

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (NASDAQ: BMRN), Zoetis (NYSE: ZTS) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Sidharth Sahoo

HSBC

€124.91→€84.76

Buy

27.31%

Upside

Reiterated

07/06/26

Zoetis price target lowered to $95 from $140 at HSBCZoetis price target lowered to $95 from $140 at HSBC

Jasper Hellweg

Argus Research

―

Hold

―

Downgraded

05/26/26

Zoetis downgraded to Hold from Buy at ArgusZoetis downgraded to Hold from Buy at Argus

Scott Schoenhaus

KeyBanc

―

Hold

―

Reiterated

05/08/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Evolent Health (NYSE: EVH), Zoetis (NYSE: ZTS) and ICU Medical (NASDAQ: ICUI)

Thomas DeBourcy

Nephron

€116.88

Hold

75.55%

Upside

Downgraded

03/05/26

Zoetis downgraded to Hold from Buy at Nephron ResearchZoetis downgraded to Hold from Buy at Nephron Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ONCBeOne Medicines

HELPHelus Pharma

ARDXArdelyx

CELCCelcuity

OMCLOmnicell

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zoetis

3 Months

Erin WrightMorgan Stanley

Success Rate

12/23 ratings generated profit

Average Return

+0.76%

Copying Erin Wright's trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +0.76% per trade.

1 Year

Steve ScalaTD Cowen

Success Rate

9/20 ratings generated profit

Average Return

-2.05%

Copying Steve Scala's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of -2.05% per trade.

2 Years

Steve ScalaTD Cowen

Success Rate

9/20 ratings generated profit

Average Return

+4.31%

Copying Steve Scala's trades and holding each position for 2 Years would result in 45.00% of your transactions generating a profit, with an average return of +4.31% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZOE Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ZOE has received 4 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ZOE average Analyst price target in the past 3 months is 80.94.

Each month's total comprises the sum of three months' worth of ratings.

ZOE Financial Forecast

ZOE Earnings Forecast

Next quarter’s earnings estimate for ZOE is €1.35 with a range of €1.30 to €1.43. The previous quarter’s EPS was €1.67. ZOE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZOE has Performed in-line its overall industry.

ZOE Sales Forecast

Next quarter’s sales forecast for ZOE is €2.05B with a range of €2.01B to €2.09B. The previous quarter’s sales results were €2.20B. ZOE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZOE has Performed in-line its overall industry.

ZOE Stock Forecast FAQ

What is DE:ZOE’s average 12-month price target, according to analysts?

Based on analyst ratings, Zoetis’s 12-month average price target is 80.94.

What is DE:ZOE’s upside potential, based on the analysts’ average price target?

Zoetis has 21.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Zoetis a Buy, Sell or Hold?

Zoetis has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 7 hold ratings and 0 sell ratings.

What is Zoetis’s share price target?

The average share price target for Zoetis is 80.94. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €102.61 ,and the lowest forecast is €71.38. The average share price target represents 21.56% Increase from the current price of €66.58.

What do analysts say about Zoetis?

Zoetis’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Zoetis?

To buy shares of DE:ZOE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Zoetis (ZOE) Stock Forecast & Price Target

ZOE Analyst Ratings

ZOE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Zoetis

ZOE Analyst Recommendation Trends

ZOE Financial Forecast

ZOE Earnings Forecast

ZOE Sales Forecast

ZOE Stock Forecast FAQ

Detailed List of Analyst Forecasts